<DOC>
	<DOCNO>NCT01963351</DOCNO>
	<brief_summary>This observational trial design assess safety profile tolerability bevacizumab combine chemotherapy first-line treatment advance recurrent non-squamous NSCLC .</brief_summary>
	<brief_title>Bevacizumab Combination With Chemotherapy Patients With Advanced Recurrent Non-squamous NSCLC</brief_title>
	<detailed_description>It observational study safety tolerability combination bevacizumab chemotherapy locally advance metastatic recurrent non-squamous non-small cell lung cancer . We try evaluate safety bevacizumab real life population lung cancer . For patient performance status 0-1 platinum base chemotherapy recommend acceptable dos bevacizumab either 7.5 15 mg/kgr . Safety profile evaluate Common Toxicity criterion v 3.0 . Especially bevacizumab evaluate specific situation thrombotic hemorrhagic event , hypertension , albuminuria , gastrointestinal disorder .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Written inform consent 2 . Age ≥18 year 3 . Able comply protocol 4 . Histologically cytologically document , locally advanced , metastatic ( Stage IV ) recurrent nonsquamous NSCLC 5.ECOG PS : 02 6 . Life expectancy ≥12 week 7 . Adequate haematological function : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L AND Platelet count ≥100 x 109/L AND Haemoglobin ≥9 g/dL ( may transfuse maintain exceed level ) 8 . Adequate liver function : Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) AND Asparagine aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &lt; 2.5 x ULN patient without liver metastasis ; &lt; 5 x ULN patient liver metastases 9 . Adequate renal function : calculated creatinine clearance ≥50 mL/min AND Urine dipstick proteinuria &lt; 2+ . 10 . INR ≤1.5 partial prothrombin time ( PTT aPTT ) ≤1.5 x ULN within 7 day prior enrolment 11 . If female , pregnant breastfeeding . Women intact uterus ( unless amenorrhoeic last 24 month ) must negative serum pregnancy test within 28 day prior enrolment study 1 . Mixed , predominant squamous component 2 . History haemoptysis , 3 month prior enrolment 3 . Evidence tumour invade major blood vessel 4 . Evidence CNS metastasis , even previously treat . If suspect , patient scan within 28 day prior enrolment rule CNS metastases 5 . Neoadjuvant/adjuvant chemotherapy within 6 month prior enrolment 6 . Radical radiotherapy curative intent within 28 day prior enrolment . Palliative radiotherapy f allow 7 . Major surgery ( include open biopsy ) , significant traumatic injury within 28 day prior enrolment 8 . Minor surgery , include insertion indwelling catheter , within 24 hour prior first bevacizumab infusion 9 . Current recent ( within 10 day first dose bevacizumab ) use aspirin ( &gt; 325mg/day ) 10 . Current recent use fulldose oral parenteral anticoagulant thrombolytic agent therapeutic purpose . Prophylactic use anticoagulant allow 11 . History evidence inherit bleed diathesis coagulopathy risk bleed 12 . Uncontrolled hypertension 13 . Clinically significant ( i.e . active ) cardiovascular disease 14 . Nonhealing wound , active peptic ulcer bone fracture 15 . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month enrolment 16 . Women intact uterus ( unless amenorrhoeic last 24 month ) use effective , mean contraception Men agree use effective contraception study 18 . Known hypersensitivity bevacizumab excipients , chemotherapy 19 . Evidence ongoing active infection , disease , neurological metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put patient high risk treatmentrelated complication 20 . Patients diagnose tracheoesophageal fistula 21 . Prior chemotherapy treatment another systemic anticancer agent 22 . Malignancies NSCLC within 5 year prior randomization , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , DCIS treat surgically curative intent 23 . History thrombotic disorder within last 6 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Non-squamous</keyword>
</DOC>